RxDoctor Payments Data

Monique Mulvany

Family · Austin, TXNPI 1710085063

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Jazz Pharmaceuticals Inc. accounts for 69.1% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $72,919, more than ten times the $2,259 reported in 2021. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$141,785in general payments, 2019–2025

Across 569 payments — averaging $249.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$98K
  • Avadel CNS Pharmaceuticals, LLC$22K
  • Harmony Biosciences LLC$21K
  • Inspire Medical Systems, Inc.$443
  • Eisai Inc.$367
  • Arbor Pharmaceuticals, Inc.$200
  • plus $218 from 3 others

What the payments were for

  • Consulting fees$21,49915%
  • Speaking & faculty fees$75,36253%
  • Travel & lodging$31,37522%
  • Food & beverage$13,0929%
  • Education$4580%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$141,785 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$54,167
Medicare patients
203
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate18$364,324
Sodium Oxybate22$303,003
XywavSodium,calcium,mag,pot Oxybate17$257,345
WakixPitolisant Hcl12$99,894
BelsomraSuvorexant70$32,301
DayvigoLemborexant34$13,470
Doxepin Hcl37$2,966
Gabapentin116$2,407
Modafinil17$2,339
Zaleplon81$1,754
Zolpidem Tartrate148$1,627
Trazodone Hcl116$1,370
Armodafinil17$1,248
Eszopiclone81$1,247
Pramipexole DihydrochloridePramipexole Di-Hcl63$928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$20,774$99,89412 claims
Eisai Inc.Dayvigo$367$13,47034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →